

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF VERMONT**

UCB, INC., UCB PHARMA GMBH, and)	
LTS LOHMANN THERAPIE-SYSTEME)	
AG)	
)	
Plaintiffs/Counterclaim)	
Defendants,)	
)	Case No. 2:22-cv-00216-CR
v.)	
)	
MYLAN TECHNOLOGIES INC.,)	
)	
Defendant/Counterclaim)	
Plaintiff.)	

**JOINT NOTICE REGARDING JUDGMENT ENTERED BY THE U.S. COURT OF
APPEALS FOR THE FEDERAL CIRCUIT**

Pursuant to paragraph 11 of the Discovery Schedule and Order (Doc. 48), Plaintiffs and Defendant submit this joint notice to notify the Court that on April 12, 2023 the U.S. Court of Appeals for the Federal Circuit issued a decision in *UCB, Inc. et al, v. Actavis Labs. UT, Inc.*, No. 2021-1924 (Fed. Cir.) (consolidated). The Federal Circuit affirmed the district court judgments, which held invalid the asserted claims of the '589 patent. The Federal Circuit's judgment and opinion are attached as Exhibit A and Exhibit B, respectively.

Dated: April 14, 2023

UCB, INC., UCB PHARMA GMBH, and LTS
LOHMANN THERAPIE-SYSTEME AG

By: /s/ Ritchie E. Berger

Ritchie E. Berger
DINSE P.C.
P.O. Box 988
Burlington, VT 05402
(802) 864-5751
rberger@dinse.com

Dated: April 14, 2023

MYLAN TECHNOLOGIES, INC.

By: /s/ Michael F. Hanley

Michael F. Hanley
PLANTE & HANLEY, P.C.
Post Office Box 708
White River Junction, VT 05001-0708
(802) 295-3151 Ext. 102
mfhanley@plantehanley.com